再激活-话题@MedSci

#再激活#

24篇内容 | 1860人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1942660, encodeId=fd7119426608b, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=ARD：乙型肝炎感染缓解患者的平均糖皮质激素剂量及HBV再激活和肝炎发作的风险, objectType=article, longId=293698, objectId=5b3f29369804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b3f29369804, replyNumber=0, likeNumber=105, createdTime=2022-12-23, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b3f29369804, moduleTitle=ARD：乙型肝炎感染缓解患者的平均糖皮质激素剂量及HBV再激活和肝炎发作的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b3f29369804)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942661, encodeId=595a1942661db, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=《2021年亚太肝病学会临床实践指南:与免疫抑制治疗相关的HBV再激活》摘译, objectType=article, longId=295205, objectId=5de729520580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5de729520580, replyNumber=0, likeNumber=67, createdTime=2022-02-09, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5de729520580, moduleTitle=《2021年亚太肝病学会临床实践指南:与免疫抑制治疗相关的HBV再激活》摘译, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5de729520580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942659, encodeId=055d1942659e2, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=CGH：37项临床试验的数据分析表明，使用DAA治疗HCV感染与VZV再激活风险增加之间无关联, objectType=article, longId=217087, objectId=67e521e08795, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67e521e08795, replyNumber=0, likeNumber=80, createdTime=2022-03-19, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67e521e08795, moduleTitle=CGH：37项临床试验的数据分析表明，使用DAA治疗HCV感染与VZV再激活风险增加之间无关联, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67e521e08795)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942658, encodeId=4989194265870, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=Blood：T细胞免疫表型的深度分析可预测HCT受体CMV再激活的风险, objectType=article, longId=157753, objectId=7c3615e753ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c3615e753ed, replyNumber=0, likeNumber=0, createdTime=2019-11-20, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c3615e753ed, moduleTitle=Blood：T细胞免疫表型的深度分析可预测HCT受体CMV再激活的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c3615e753ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942657, encodeId=37a0194265e9c, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=Clinical Gastro H：长期接受肿瘤坏死因子拮抗剂治疗的患者乙型肝炎病毒再激活和肝毒性的发生率, objectType=article, longId=155520, objectId=b82d1555203b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b82d1555203b, replyNumber=0, likeNumber=69, createdTime=2019-09-28, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b82d1555203b, moduleTitle=Clinical Gastro H：长期接受肿瘤坏死因子拮抗剂治疗的患者乙型肝炎病毒再激活和肝毒性的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b82d1555203b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942654, encodeId=199e19426549e, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=Liver Int：HCV患者在接受直接抗病毒治疗过程中，HBV再激活的风险, objectType=article, longId=138064, objectId=bdd0138064e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdd0138064e2, replyNumber=0, likeNumber=68, createdTime=2018-12-08, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdd0138064e2, moduleTitle=Liver Int：HCV患者在接受直接抗病毒治疗过程中，HBV再激活的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdd0138064e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942652, encodeId=6809194265237, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=Blood：BTKCys481Ser突变通过再激活ERK1/2驱动恶性B细胞产生依鲁替尼耐药性，并通过旁分泌对未突变细胞产生保护作用, objectType=article, longId=131375, objectId=baed1313e5b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=baed1313e5b2, replyNumber=0, likeNumber=0, createdTime=2018-08-28, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=baed1313e5b2, moduleTitle=Blood：BTKCys481Ser突变通过再激活ERK1/2驱动恶性B细胞产生依鲁替尼耐药性，并通过旁分泌对未突变细胞产生保护作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=baed1313e5b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942651, encodeId=f5b8194265111, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=Lancet Gastroen Hepatol：HCV抗病毒治疗过程中的HBV再激活风险, objectType=article, longId=127564, objectId=bc6c12e56400, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc6c12e56400, replyNumber=0, likeNumber=83, createdTime=2018-12-27, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc6c12e56400, moduleTitle=Lancet Gastroen Hepatol：HCV抗病毒治疗过程中的HBV再激活风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc6c12e56400)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942655, encodeId=3e9a194265529, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=2018 共识报告：免疫抑制治疗和乙型肝炎再激活风险, objectType=article, longId=138455, objectId=3f8213845565, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f8213845565, replyNumber=0, likeNumber=48, createdTime=2019-01-29, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f8213845565, moduleTitle=2018 共识报告：免疫抑制治疗和乙型肝炎再激活风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f8213845565)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942656, encodeId=6aef1942656d0, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=J Viral Hepat：DAA治疗HBV和HCV共感染代偿期肝硬化患者时，HBV病毒再激活的风险, objectType=article, longId=145196, objectId=e18514519623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e18514519623, replyNumber=0, likeNumber=102, createdTime=2019-02-03, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e18514519623, moduleTitle=J Viral Hepat：DAA治疗HBV和HCV共感染代偿期肝硬化患者时，HBV病毒再激活的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e18514519623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942648, encodeId=1e4e1942648da, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=JAMA Inter Med：免疫功能危重症患者巨细胞病毒再激活的抗病毒治疗, objectType=article, longId=97684, objectId=7bb89e684e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bb89e684e6, replyNumber=0, likeNumber=83, createdTime=2017-07-26, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bb89e684e6, moduleTitle=JAMA Inter Med：免疫功能危重症患者巨细胞病毒再激活的抗病毒治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bb89e684e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942653, encodeId=9840194265332, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=Transpl Int：肝移植受者的巨细胞病毒再激活与较高的心血管风险有关, objectType=article, longId=132040, objectId=9903132040e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9903132040e4, replyNumber=0, likeNumber=0, createdTime=2019-02-08, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9903132040e4, moduleTitle=Transpl Int：肝移植受者的巨细胞病毒再激活与较高的心血管风险有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9903132040e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942650, encodeId=737c1942650f4, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=《2017年意大利共识指南：血液系统恶性肿瘤以及接受造血干细胞移植患者HBV再激活的筛查、监测、预防和预防性治疗的建议》摘译, objectType=article, longId=120876, objectId=6b8d1208e6ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b8d1208e6ba, replyNumber=0, likeNumber=65, createdTime=2018-09-18, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b8d1208e6ba, moduleTitle=《2017年意大利共识指南：血液系统恶性肿瘤以及接受造血干细胞移植患者HBV再激活的筛查、监测、预防和预防性治疗的建议》摘译, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b8d1208e6ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942649, encodeId=a9191942649e6, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=Oncogene：雄激素受体调控的脂质合成再激活可促使去势难治性前列腺癌的恶化, objectType=article, longId=118804, objectId=677b1188048a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=677b1188048a, replyNumber=0, likeNumber=103, createdTime=2018-02-05, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=677b1188048a, moduleTitle=Oncogene：雄激素受体调控的脂质合成再激活可促使去势难治性前列腺癌的恶化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=677b1188048a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942647, encodeId=d263194264e30, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=JCEM ：暴发性1型糖尿病与人类巨细胞病毒的再激活有关, objectType=article, longId=96195, objectId=a6ba96195c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6ba96195c5, replyNumber=0, likeNumber=102, createdTime=2018-01-30, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6ba96195c5, moduleTitle=JCEM ：暴发性1型糖尿病与人类巨细胞病毒的再激活有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6ba96195c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942646, encodeId=ced8194264601, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=Hepatology：隐性HBV携带者干细胞移植后再激活的前瞻性研究, objectType=article, longId=93481, objectId=9d5793481d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d5793481d8, replyNumber=0, likeNumber=78, createdTime=2017-09-08, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d5793481d8, moduleTitle=Hepatology：隐性HBV携带者干细胞移植后再激活的前瞻性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d5793481d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942645, encodeId=a992194264592, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=JAMA：抑制化疗患者HBV再激活？恩替卡韦显优势, objectType=article, longId=44347, objectId=fe834434eb5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe834434eb5, replyNumber=0, likeNumber=100, createdTime=2015-06-04, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe834434eb5, moduleTitle=JAMA：抑制化疗患者HBV再激活？恩替卡韦显优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe834434eb5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942643, encodeId=f44619426431f, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=CROH：免疫抑制相关HBV再激活的机制与预防, objectType=article, longId=29349, objectId=52412934975, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52412934975, replyNumber=0, likeNumber=75, createdTime=2014-09-10, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52412934975, moduleTitle=CROH：免疫抑制相关HBV再激活的机制与预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52412934975)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942644, encodeId=bbdc194264462, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=乙肝病毒再激活的发病率、致病机制和预防, objectType=article, longId=30706, objectId=e55030e063d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e55030e063d, replyNumber=0, likeNumber=84, createdTime=2014-08-14, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e55030e063d, moduleTitle=乙肝病毒再激活的发病率、致病机制和预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e55030e063d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1942640, encodeId=89f6194264015, content=<a href='/topic/show?id=7df230644bd' target=_blank style='color:#2F92EE;'>#再激活#</a>, objectTitle=J Viral Hepat：抗病毒药物预防性治疗可降低HBcAb+患者HBV再激活风险, objectType=article, longId=24519, objectId=cec624519e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cec624519e6, replyNumber=0, likeNumber=95, createdTime=2014-02-07, rootId=0, userName=xlysu, userId=3f54230, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cec624519e6, moduleTitle=J Viral Hepat：抗病毒药物预防性治疗可降低HBcAb+患者HBV再激活风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cec624519e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

再激活

2020-05-29

xlysu (审核中...)

前往app查看评论内容

#再激活#

ARD：乙型肝炎感染缓解患者的平均糖皮质激素剂量及HBV再激活和肝炎发作的风险

2022-12-23

xlysu (审核中...)

前往app查看评论内容

#再激活#

《2021年亚太肝病学会临床实践指南:与免疫抑制治疗相关的HBV再激活》摘译

2022-02-09

xlysu (审核中...)

前往app查看评论内容

#再激活#

CGH：37项临床试验的数据分析表明，使用DAA治疗HCV感染与VZV再激活风险增加之间无关联

2022-03-19

xlysu (审核中...)

前往app查看评论内容

#再激活#

Blood：T细胞免疫表型的深度分析可预测HCT受体CMV再激活的风险

2019-11-20

xlysu (审核中...)

前往app查看评论内容

#再激活#

Clinical Gastro H：长期接受肿瘤坏死因子拮抗剂治疗的患者乙型肝炎病毒再激活和肝毒性的发生率

2019-09-28

xlysu (审核中...)

前往app查看评论内容

#再激活#

Liver Int：HCV患者在接受直接抗病毒治疗过程中，HBV再激活的风险

2018-12-08

xlysu (审核中...)

前往app查看评论内容

#再激活#

Blood：BTKCys481Ser突变通过再激活ERK1/2驱动恶性B细胞产生依鲁替尼耐药性，并通过旁分泌对未突变细胞产生保护作用

2018-08-28

xlysu (审核中...)

前往app查看评论内容

#再激活#

Lancet Gastroen Hepatol：HCV抗病毒治疗过程中的HBV再激活风险

2018-12-27

xlysu (审核中...)

前往app查看评论内容

#再激活#

2018 共识报告：免疫抑制治疗和乙型肝炎再激活风险

2019-01-29

xlysu (审核中...)

前往app查看评论内容

#再激活#

J Viral Hepat：DAA治疗HBV和HCV共感染代偿期肝硬化患者时，HBV病毒再激活的风险

2019-02-03

xlysu (审核中...)

前往app查看评论内容

#再激活#

JAMA Inter Med：免疫功能危重症患者巨细胞病毒再激活的抗病毒治疗

2017-07-26

xlysu (审核中...)

前往app查看评论内容

#再激活#

Transpl Int：肝移植受者的巨细胞病毒再激活与较高的心血管风险有关

2019-02-08

xlysu (审核中...)

前往app查看评论内容

#再激活#

《2017年意大利共识指南：血液系统恶性肿瘤以及接受造血干细胞移植患者HBV再激活的筛查、监测、预防和预防性治疗的建议》摘译

2018-09-18

xlysu (审核中...)

前往app查看评论内容

#再激活#

Oncogene：雄激素受体调控的脂质合成再激活可促使去势难治性前列腺癌的恶化

2018-02-05

xlysu (审核中...)

前往app查看评论内容

#再激活#

JCEM ：暴发性1型糖尿病与人类巨细胞病毒的再激活有关

2018-01-30

xlysu (审核中...)

前往app查看评论内容

#再激活#

Hepatology：隐性HBV携带者干细胞移植后再激活的前瞻性研究

2017-09-08

xlysu (审核中...)

前往app查看评论内容

#再激活#

JAMA：抑制化疗患者HBV再激活？恩替卡韦显优势

2015-06-04

xlysu (审核中...)

前往app查看评论内容

#再激活#

CROH：免疫抑制相关HBV再激活的机制与预防

2014-09-10

xlysu (审核中...)

前往app查看评论内容

#再激活#

乙肝病毒再激活的发病率、致病机制和预防

2014-08-14

xlysu (审核中...)

前往app查看评论内容

#再激活#

J Viral Hepat：抗病毒药物预防性治疗可降低HBcAb+患者HBV再激活风险

2014-02-07

科室
- - 订阅+
  - 更多科室
工具
服务